

Javier Ampuero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6382588/publications.pdf>

Version: 2024-02-01

105
papers

2,971
citations

172457

29
h-index

189892

50
g-index

113
all docs

113
docs citations

113
times ranked

4263
citing authors

#	ARTICLE	IF	CITATIONS
1	Consenso AEEH «Consenso sobre métodos de detección y derivación de enfermedades hepáticas prevalentes ocultas». Gastroenterología Y Hepatología, 2023, 46, 236-247.	0.5	2
2	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. Gut, 2022, 71, 382-390.	12.1	113
3	A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. American Journal of Gastroenterology, 2022, 117, 138-146.	0.4	8
4	Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function. Journal of Hepatology, 2022, 76, 11-24.	3.7	16
5	Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis. European Journal of Internal Medicine, 2022, 98, 53-60.	2.2	4
6	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. Journal of Hepatology, 2022, 76, 1013-1020.	3.7	66
7	Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies. Journal of Clinical and Translational Hepatology, 2022, 10, 356-362.	1.4	6
8	Long non-coding RNA H19 as a biomarker for hepatocellular carcinoma. Liver International, 2022, 42, 1410-1422.	3.9	14
9	Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation. Scientific Reports, 2022, 12, 3418.	3.3	19
10	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). Gastroenterología Y Hepatología, 2022, 45, 724-734.	0.5	3
11	Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD. Journal of Gastroenterology, 2022, 57, 357-371.	5.1	8
12	A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy. Cancers, 2022, 14, 192.	3.7	15
13	Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes. Gut, 2022, 71, 2138-2140.	12.1	9
14	General Overview About the Current Management of Nonalcoholic Fatty Liver Disease. Clinical Drug Investigation, 2022, 42, 39-45.	2.2	4
15	Correction to: A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. American Journal of Gastroenterology, 2022, 117, 819-819.	0.4	0
16	Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology. Liver International, 2022, 42, 1783-1792.	3.9	10
17	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	2.9	46
18	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 806-815.e5.	4.4	90

#	ARTICLE	IF	CITATIONS
19	Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation. <i>Clinical and Translational Medicine</i> , 2021, 11, e275.	4.0	0
20	COVID-19 and the liver: The chicken or the egg dilemma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, 113, 555.	0.3	0
21	Looking for a new name for Non-alcoholic fatty liver disease in Spanish: Esteatosis Hepática Metabólica (EHmet). <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, 113, 161-163.	0.3	10
22	An Experimental DUAL Model of Advanced Liver Damage. <i>Hepatology Communications</i> , 2021, 5, 1051-1068.	4.3	11
23	Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1754-1768.	2.8	5
24	Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1238-1247.	0.4	12
25	Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD". <i>Journal of Hepatology</i> , 2021, 74, 971-972.	3.7	0
26	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021, 41, 2076-2086.	3.9	13
27	Management of NAFLD patients with advanced fibrosis. <i>Liver International</i> , 2021, 41, 95-104.	3.9	7
28	Wilson's disease: Revisiting an old friend. <i>World Journal of Hepatology</i> , 2021, 13, 634-649.	2.0	28
29	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	3.7	149
30	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	3.7	100
31	Entwicklung und Validierung des NAFLD Cirrhosis Score (NCS) zur Separierung von fortgeschrittener Fibrose und Zirrhose. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.5	0
32	Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 667354.	4.8	7
33	Impact of COVID-19 on liver disease: From the experimental to the clinic perspective. <i>World Journal of Virology</i> , 2021, 10, 301-311.	2.9	3
34	Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 519-530.	3.7	17
35	Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients. <i>World Journal of Gastroenterology</i> , 2021, 27, 8343-8356.	3.3	1
36	Development and Validation of Hepamet Fibrosis Scoring System "A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	4.4	104

#	ARTICLE	IF	CITATIONS
37	Oral glutamine challenge is a marker of altered ammonia metabolism and predicts the risk of hepatic encephalopathy. <i>Liver International</i> , 2020, 40, 921-930.	3.9	5
38	Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00203.	2.5	21
39	Stratification of patients in NASH clinical trials: A pitfall for trial success. <i>JHEP Reports</i> , 2020, 2, 100148.	4.9	20
40	Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. <i>Liver International</i> , 2020, 40, 2182-2193.	3.9	14
41	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25.	3.7	59
42	COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 389-396.	0.3	20
43	Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 975-985.	0.4	3
44	One-step diagnosis. A key tool for the elimination of hepatitis C. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 513-514.	0.3	1
45	The Spectrum of NAFLD: From the Organ to the System. , 2020, , 1-10.		0
46	Impact of liver injury on the severity of COVID-19: Systematic Review with Meta-analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 113, 125-135.	0.3	17
47	Sofosbuvir/velpatasvir for 12-weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. <i>Journal of Hepatology</i> , 2019, 71, 660-665.	3.7	93
48	Calidad de vida en los pacientes con hepatitis C. Importancia del tratamiento. <i>GastroenterologÃa Y HepatologÃa</i> , 2019, 42, 20-25.	0.5	1
49	Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 301-307.	0.3	2
50	Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 270-274.	0.3	2
51	Editorial: looking for patients at risk of cirrhosis in the general populationâ€”many needles in a haystack. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 692-694.	3.7	4
52	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502.	4.4	83
53	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , 2018, 68, 940-948.	3.7	15
54	Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1774341.	3.2	9

#	ARTICLE	IF	CITATIONS
55	Diagnostic accuracy of <scp>SCCA</scp> and <scp>SCCA</scp>â€lgM for hepatocellular carcinoma: A metaâ€analysis. <i>Liver International</i> , 2018, 38, 1820-1831.	3.9	18
56	Solving doubts about Lâ€ornithine Lâ€aspartate for overt hepatic encephalopathy: Whom and how to treat. <i>Hepatology</i> , 2018, 67, 476-478.	7.3	6
57	Nuevas perspectivas terapÃ©uticas en la esteatohepatitis no alcohÃ³lica. <i>GastroenterologÃa Y HepatologÃa</i> , 2018, 41, 128-142.	0.5	10
58	Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 718-725.	2.8	34
59	Peer-to-Peer Sessions in Primary Care to Improve the Hepatitis B Detection Rate in Seville, Spain. <i>Annals of Hepatology</i> , 2018, 17, 864-870.	1.5	3
60	The effects of metabolic status on nonâ€alcoholic fatty liver diseaseâ€related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1260-1270.	3.7	70
61	miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2018, 69, 1335-1348.	3.7	121
62	Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. <i>PLoS ONE</i> , 2018, 13, e0191805.	2.5	33
63	Metformin modifies glutamine metabolism in an in vitro and in vivo model of hepatic encephalopathy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 427-433.	0.3	3
64	Usefulness of bioelectrical impedance analysis for monitoring patients with refractory ascites. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 111, 223-227.	0.3	4
65	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 945-949.e1.	4.4	22
66	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. <i>Journal of Hepatology</i> , 2017, 66, 1138-1148.	3.7	159
67	Effectiveness and safety of sofosbuvirâ€based regimens plus an <scp>NS</scp>5A inhibitor for patients with <scp>HCV</scp> genotype 3 infection and cirrhosis. Results of a multicenter realâ€life cohort. <i>Journal of Viral Hepatitis</i> , 2017, 24, 304-311.	2.0	40
68	Effectiveness and safety of ombitasvir, paritaprevir, ritonavir Â± dasabuvir Â± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2017, 24, 226-237.	2.0	22
69	Lactulose reduces bacterial <scp>DNA</scp> translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. <i>Liver International</i> , 2017, 37, 212-223.	3.9	28
70	Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. <i>World Journal of Hepatology</i> , 2017, 9, 697.	2.0	8
71	Acute-on-chronic liver failure: A time to step forward. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 397-398.	0.3	1
72	Low phase angle is associated with the development of hepatic encephalopathy in patients with cirrhosis. <i>World Journal of Gastroenterology</i> , 2016, 22, 10064.	3.3	28

#	ARTICLE	IF	CITATIONS
73	Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1611-1618.	2.8	25
74	Case Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis. <i>Seminars in Liver Disease</i> , 2016, 36, 181-186.	3.6	2
75	New technologies – new insights into the pathogenesis of hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2016, 31, 1259-1267.	2.9	8
76	Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. <i>Clinical Microbiology and Infection</i> , 2016, 22, 839-845.	6.0	42
77	Remission maintained by monotherapy after biological+immunosuppressive combination for Crohn's disease in clinical practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 112-118.	2.8	10
78	Pharmacogenetics of ribavirin-induced anemia in hepatitis C. <i>Pharmacogenomics</i> , 2016, 17, 1587-1594.	1.3	10
79	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016, 6, 31421.	3.3	33
80	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016, 64, 390-398.	3.7	64
81	Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. <i>World Journal of Gastroenterology</i> , 2016, 22, 5285.	3.3	10
82	Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin. <i>World Journal of Hepatology</i> , 2015, 7, 1105.	2.0	31
83	Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study. <i>PLoS ONE</i> , 2015, 10, e0122613.	2.5	2
84	Assessing cardiovascular risk in hepatitis C: An unmet need. <i>World Journal of Hepatology</i> , 2015, 7, 2214.	2.0	22
85	Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. <i>Journal of Clinical Virology</i> , 2015, 68, 56-60.	3.1	11
86	Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection. <i>Genes and Immunity</i> , 2015, 16, 297-300.	4.1	10
87	Interferon- γ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , 2015, 6, 6422.	12.8	156
88	Minimal Hepatic Encephalopathy and Critical Flicker Frequency Are Associated With Survival of Patients With Cirrhosis. <i>Gastroenterology</i> , 2015, 149, 1483-1489.	1.3	108
89	Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 845-857.	2.2	14
90	Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 107, 10-6.	0.3	64

#	ARTICLE	IF	CITATIONS
91	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014, 13, 356-363.	1.5	18
92	Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 291-295.	2.8	36
93	Deciphering the Spectrum of Low-Grade Hepatic Encephalopathy in Clinical Practice. <i>Gastroenterology</i> , 2014, 146, 887-890.	1.3	7
94	Stanozolol-induced bland cholestasis. <i>Gastroenterology & Hepatology</i> , 2014, 37, 71-72.	0.5	10
95	P219 FINE MAPPING OF THE BUTYROPHILIN GENOMICS REGION: ROLE IN HEPATITIS C VIRUS INFECTION (HCV). <i>Journal of Hepatology</i> , 2014, 60, S139.	3.7	2
96	Review article: <scp>HCV</scp> genotype 3 “ the new treatment challenge. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 686-698.	3.7	103
97	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014, 13, 356-63.	1.5	12
98	LPAC syndrome associated with deletion of the full exon 4 in a ABCB4 genetic mutation in a patient with hepatitis C. <i>Revista Espanola De Enfermedades Digestivas</i> , 2014, 106, 544-7.	0.3	2
99	Role of diabetes mellitus on hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2013, 28, 277-279.	2.9	30
100	Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 74-80.	3.7	18
101	Meta-analysis: pegylated interferon α achieves higher early virological responses than β in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1065-1073.	3.7	6
102	Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver. <i>World Journal of Gastroenterology</i> , 2013, 19, 7327.	3.3	103
103	Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables. <i>Annals of Hepatology</i> , 2013, 12, 420-430.	1.5	32
104	Unsedated colonoscopy: an option for some but not for all. <i>Gastrointestinal Endoscopy</i> , 2012, 76, 699.	1.0	2
105	Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy. <i>PLoS ONE</i> , 2012, 7, e49279.	2.5	55